Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine

Mariangela Miele, Stefano Bonassi, Stefania Bonatti, Elena Martini, Luigi Miglio, Laura Ottaggio, Paola Queirolo, Mario R. Sertoli, Angelo Abbondandolo

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Dacarbazine is an antitumour drug used with considerable success in the chemotherapy of a number of human neoplasias, particularly advanced disseminated melanoma. Dacarbazine is mutagenic in prokaryotic and eukaryotic cells, but no effect in vivo have been evaluated. Materials and methods: Peripheral blood lymphocytes from patients with metastatic melanoma undergoing dacarbazine chemotherapy every 21 days for a total of 7 cycles, were analysed for the presence of micronuclei with the CREST antikinetochore antibody technique. Cytogenetic analysis on blood samples collected just before and 2 hours after the therapy was carried out at 48, 72 and 96 hours following lymphocyte stimulation. Results: A significant increase in micronucleus frequency was found at both 72 and 96 hours after therapy. For the only two patients analysed after more than one cycle, a decrease in micronuclei was observed after the third and the fourth therapy. Moreover, the CREST antibody technique showed that the frequency of micronuclei containing whole chromosomes (CREST+) was significantly higher after therapy at 72 and 96 hours. As the frequency of micronuclei containing acentric chromosome fragments (CREST-) was not significantly increased after therapy, either at 72 or 96 hours after lymphocyte stimulation, we suppose that DTIC mainly acted as an aneugenic agent. Conclusions: The lack of a significant micronucleus increase at 48 hours could suggest that this culture time is too short for providing cultures with a sufficient large number of diving cells. In conclusion, our results have shown that dacarbazine induced chromosome loss in lymphocytes from patients treated with this drug.

Original languageEnglish
Pages (from-to)1967-1971
Number of pages5
JournalAnticancer Research
Volume18
Issue number3 B
Publication statusPublished - May 1998

Fingerprint

Dacarbazine
Melanoma
Lymphocytes
Chromosomes
Lymphocyte Activation
Aneugens
Prokaryotic Cells
Therapeutics
Drug Therapy
Diving
Antibodies
Cytogenetic Analysis
Eukaryotic Cells
Antineoplastic Agents
Cell Count
Pharmaceutical Preparations
Neoplasms

Keywords

  • Dacarbazine
  • Melanoma
  • Micronucleus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miele, M., Bonassi, S., Bonatti, S., Martini, E., Miglio, L., Ottaggio, L., ... Abbondandolo, A. (1998). Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine. Anticancer Research, 18(3 B), 1967-1971.

Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine. / Miele, Mariangela; Bonassi, Stefano; Bonatti, Stefania; Martini, Elena; Miglio, Luigi; Ottaggio, Laura; Queirolo, Paola; Sertoli, Mario R.; Abbondandolo, Angelo.

In: Anticancer Research, Vol. 18, No. 3 B, 05.1998, p. 1967-1971.

Research output: Contribution to journalArticle

Miele, M, Bonassi, S, Bonatti, S, Martini, E, Miglio, L, Ottaggio, L, Queirolo, P, Sertoli, MR & Abbondandolo, A 1998, 'Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine', Anticancer Research, vol. 18, no. 3 B, pp. 1967-1971.
Miele M, Bonassi S, Bonatti S, Martini E, Miglio L, Ottaggio L et al. Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine. Anticancer Research. 1998 May;18(3 B):1967-1971.
Miele, Mariangela ; Bonassi, Stefano ; Bonatti, Stefania ; Martini, Elena ; Miglio, Luigi ; Ottaggio, Laura ; Queirolo, Paola ; Sertoli, Mario R. ; Abbondandolo, Angelo. / Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine. In: Anticancer Research. 1998 ; Vol. 18, No. 3 B. pp. 1967-1971.
@article{ce5c5cdab6984455a899c0ae8bb4d6ba,
title = "Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine",
abstract = "Background: Dacarbazine is an antitumour drug used with considerable success in the chemotherapy of a number of human neoplasias, particularly advanced disseminated melanoma. Dacarbazine is mutagenic in prokaryotic and eukaryotic cells, but no effect in vivo have been evaluated. Materials and methods: Peripheral blood lymphocytes from patients with metastatic melanoma undergoing dacarbazine chemotherapy every 21 days for a total of 7 cycles, were analysed for the presence of micronuclei with the CREST antikinetochore antibody technique. Cytogenetic analysis on blood samples collected just before and 2 hours after the therapy was carried out at 48, 72 and 96 hours following lymphocyte stimulation. Results: A significant increase in micronucleus frequency was found at both 72 and 96 hours after therapy. For the only two patients analysed after more than one cycle, a decrease in micronuclei was observed after the third and the fourth therapy. Moreover, the CREST antibody technique showed that the frequency of micronuclei containing whole chromosomes (CREST+) was significantly higher after therapy at 72 and 96 hours. As the frequency of micronuclei containing acentric chromosome fragments (CREST-) was not significantly increased after therapy, either at 72 or 96 hours after lymphocyte stimulation, we suppose that DTIC mainly acted as an aneugenic agent. Conclusions: The lack of a significant micronucleus increase at 48 hours could suggest that this culture time is too short for providing cultures with a sufficient large number of diving cells. In conclusion, our results have shown that dacarbazine induced chromosome loss in lymphocytes from patients treated with this drug.",
keywords = "Dacarbazine, Melanoma, Micronucleus",
author = "Mariangela Miele and Stefano Bonassi and Stefania Bonatti and Elena Martini and Luigi Miglio and Laura Ottaggio and Paola Queirolo and Sertoli, {Mario R.} and Angelo Abbondandolo",
year = "1998",
month = "5",
language = "English",
volume = "18",
pages = "1967--1971",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - Micronucleus analysis in peripheral blood lymphocytes from melanoma patients treated with dacarbazine

AU - Miele, Mariangela

AU - Bonassi, Stefano

AU - Bonatti, Stefania

AU - Martini, Elena

AU - Miglio, Luigi

AU - Ottaggio, Laura

AU - Queirolo, Paola

AU - Sertoli, Mario R.

AU - Abbondandolo, Angelo

PY - 1998/5

Y1 - 1998/5

N2 - Background: Dacarbazine is an antitumour drug used with considerable success in the chemotherapy of a number of human neoplasias, particularly advanced disseminated melanoma. Dacarbazine is mutagenic in prokaryotic and eukaryotic cells, but no effect in vivo have been evaluated. Materials and methods: Peripheral blood lymphocytes from patients with metastatic melanoma undergoing dacarbazine chemotherapy every 21 days for a total of 7 cycles, were analysed for the presence of micronuclei with the CREST antikinetochore antibody technique. Cytogenetic analysis on blood samples collected just before and 2 hours after the therapy was carried out at 48, 72 and 96 hours following lymphocyte stimulation. Results: A significant increase in micronucleus frequency was found at both 72 and 96 hours after therapy. For the only two patients analysed after more than one cycle, a decrease in micronuclei was observed after the third and the fourth therapy. Moreover, the CREST antibody technique showed that the frequency of micronuclei containing whole chromosomes (CREST+) was significantly higher after therapy at 72 and 96 hours. As the frequency of micronuclei containing acentric chromosome fragments (CREST-) was not significantly increased after therapy, either at 72 or 96 hours after lymphocyte stimulation, we suppose that DTIC mainly acted as an aneugenic agent. Conclusions: The lack of a significant micronucleus increase at 48 hours could suggest that this culture time is too short for providing cultures with a sufficient large number of diving cells. In conclusion, our results have shown that dacarbazine induced chromosome loss in lymphocytes from patients treated with this drug.

AB - Background: Dacarbazine is an antitumour drug used with considerable success in the chemotherapy of a number of human neoplasias, particularly advanced disseminated melanoma. Dacarbazine is mutagenic in prokaryotic and eukaryotic cells, but no effect in vivo have been evaluated. Materials and methods: Peripheral blood lymphocytes from patients with metastatic melanoma undergoing dacarbazine chemotherapy every 21 days for a total of 7 cycles, were analysed for the presence of micronuclei with the CREST antikinetochore antibody technique. Cytogenetic analysis on blood samples collected just before and 2 hours after the therapy was carried out at 48, 72 and 96 hours following lymphocyte stimulation. Results: A significant increase in micronucleus frequency was found at both 72 and 96 hours after therapy. For the only two patients analysed after more than one cycle, a decrease in micronuclei was observed after the third and the fourth therapy. Moreover, the CREST antibody technique showed that the frequency of micronuclei containing whole chromosomes (CREST+) was significantly higher after therapy at 72 and 96 hours. As the frequency of micronuclei containing acentric chromosome fragments (CREST-) was not significantly increased after therapy, either at 72 or 96 hours after lymphocyte stimulation, we suppose that DTIC mainly acted as an aneugenic agent. Conclusions: The lack of a significant micronucleus increase at 48 hours could suggest that this culture time is too short for providing cultures with a sufficient large number of diving cells. In conclusion, our results have shown that dacarbazine induced chromosome loss in lymphocytes from patients treated with this drug.

KW - Dacarbazine

KW - Melanoma

KW - Micronucleus

UR - http://www.scopus.com/inward/record.url?scp=0031901851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031901851&partnerID=8YFLogxK

M3 - Article

C2 - 9677451

AN - SCOPUS:0031901851

VL - 18

SP - 1967

EP - 1971

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -